Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

David Nield is a technology journalist from Manchester in the U.K. who has been writing about gadgets and apps for more than 20 years. He has a bachelor's degree in English Literature from Durham ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Gemini Can Now Generate 30-Second Songs From Text, Images with Lyria 3 You don't have to provide the lyrics. Just mention the mood and tempo or upload an image for reference, and let Lyria 3 do the ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Investing.com - Generate Biomedicines, Inc. filed to raise up to $425 million in an initial public offering on The Nasdaq Stock Market under the symbol "GENB." The clinical-stage generative biology ...

The destination of the Six Nations title will be decided in the final match of the tournament with three teams in the hunt going into “Super Saturday”. Scotland, though, are OUT of the title chase ...

Dina Zipin has 10+ years of experience as a writer and editor and 2+ years as the head writer/creative strategist for Uproxx Media. Suzanne is a content marketer, writer, and fact-checker. She holds a ...